Pfizer Plans US$650 Million Manufacturing Technology Center at Groton R&D Campus in Connecticut
Introduction
Pfizer plans to build a Manufacturing Technology Center at its research and development campus in Groton, Connecticut, representing a US$650 million capital investment over the next five years. The facility will produce clinical active pharmaceutical ingredients (APIs) and drug products to support Pfizer-sponsored clinical trials worldwide.
Features
The approximately 220,000-square-foot facility will be located on Pfizer's Groton campus, one of the company's major research and development centres supporting scientific discovery, pharmaceutical sciences, clinical development and the global supply of clinical research materials.
The centre will manufacture clinical APIs and drug products for Pfizer-sponsored clinical trials around the world, linking early-stage scientific discovery with advanced manufacturing capabilities.
Construction is planned to begin in the second quarter of 2027, with operational startup targeted for mid-2031.
The project will consolidate employees currently working in other facilities across the Groton campus into a modern, purpose-built centre. It will modernise the infrastructure supporting Pfizer's existing workforce and bring related operations together in a facility designed for the company's future clinical manufacturing needs.
The investment was announced by AdvanceCT, Connecticut's economic development organisation, and the City of Groton will continue to support Pfizer as the project advances through planning, construction and operational startup.
Specifications
| Name | Pfizer Manufacturing Technology Center – Groton |
| Type | Construction (Clinical API and Drug Product Manufacturing Facility) |
| Budget | US$650 million |
